主页 > 医学信息 >
【medical-news】Key Medical Journal Publishes New Strategy
1/31/2007
关键医学杂志发表抵御耐药病原体的新策略
Source: Immune Biologics, Inc.
来源：免疫生物学公司
The proliferation of bacteria that have grown resistant to even the newest antibiotics poses a new and very dangerous threat to public health. The results of treating infected mice in a double blind study at the University of Arizona with Bioengineered Lacteal Complex (BLC) is published as "A Pilot Study of an anti-MRSA Bio-Engineered Lacteal Complex (anti-MRSA BLC) in a Murine Septicemia Model" co-authored by Jesse A. Stoff, MD, David E. Nix, MD and D.W. DeYoung, DVM in the new issue of the journal "Immunopharmacology and Immunotoxicology" released on December 29, 2006. In the face of this evolving threat an Arizona company, Immune Biologics, Inc., has acquired rights for the development and use of BLC's from the research group Sixty-Eight, LLC headed by Jesse A. Stoff, MD. BLC's are derived from the milk of dairy cows.
现在甚至已经出现了对现在最新的抗生素的耐药株，这些耐药株的增殖对公共卫生构成了相当大的威胁。亚利桑那州大学的一项治疗小鼠的双盲试验研究结果发表在2006年12月29日的免疫药理学和免疫毒理学杂志上，文章题目为“抗-MRSA生物工程乳糜管复合体（BLC）在鼠败血症模型中的初步研究”，共同作者为：Jesse A. Stoff医学博士，David E. Nix医学博士和D.W. DeYoung。面对进化的威胁，一家亚利桑那州的公司，免疫生物学公司从Jesse A. Stoff领导的Sixty-Eight, LLC 研究小组获得了开发和使用BLC的权利，BLC来源于牛奶场的牛奶。
The Company's BLC is described as offering distinct advantages over traditional antibiotics and other strategies and paradigms for the treatment of infectious disease. BLC's use the immune system to launch their response, do not attack non-pathogenic organisms, can be used as a preventative strategy, can be used on multiple occasions without loss of efficacy with great safety, do not compromise the immune function of the user and perhaps most importantly they can be developed and brought to market in timelines as short as a few weeks. The first product, for the treatment of MRSA (Methicillin-resistant Staphhylococcus aureus), is sorely needed by healthcare workers and patients worldwide. The Company, in conjunction with Biologics Consulting Group, LLC, Toxikon, Inc. and the University of Arizona is currently collaborating for development funding with the United States Department of Defense, seeking venture capital and preparing for presentation to the United States Food and Drug Administration.
公司声称BLC治疗效果优于传统抗生素，其治疗感染病策略和和范例也优于其它的治疗。BLC作用于免疫系统，启动免疫反应，不攻击非致病性病原体，可作为预防性使用，可反复使用而且安全有效，不会危害免疫功能，可能最重要的是，他们将在几周内把产品开发出来进入市场。第一个产品，治疗MRSA（耐甲氧西林金黄色葡萄球菌），是全世界医务人员和病人都急需的。该公司与Toxikon公司生物咨询部和亚利桑那大学LLC联合，正共同为美国国防部发展基金研究和寻找问题的关键，并准备呈报美国食品药品监督局。
Specialized BLC's are being developed under rights acquired by Immune Biologics, Inc. of Phoenix, Arizona.
亚利桑那州凤凰城的免疫生物学公司拥有特异性BLC的开发权。 [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-08-13 17:12
医学,生命科学网